CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...